Umbilical cord blood treatment for cancer has made a new breakthrough
Recently, scientists have made a new progress in making cord blood transplantation for safer and more effective patients with leukemia and lymphoma. The relevant results were published in the journal Blood (Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation), and accompanied by a review article entitled "Let the cord blood breathe fresh air". Through a small clinical trial, scientists have discovered the importance of a hormone called erythropoietin (EPO) in cord blood transplantation. Reducing human EPO levels contributes to a process called homing. Through this process, newly transplanted hematopoietic stem cells migrate into the patient's bone marrow and begin to repair the body's ability to produce healthy blood cells and immune cells. At present, one of the challenges of cord blood transplantation is that cord blood takes a long time to return to the bone marrow, and only a few cells can reach their "destination." Researchers have been looking for strategies to overcome this limitation. In this effort, scientists have found that cord blood transplantation can be improved by blocking EPO-EPO receptor signaling. This clinical trial included a total of 15 patients. Before receiving cord blood transplantation, the researchers first blocked the EPO signal in cancer patients by hyperbaric oxygen therapy. Specifically, oxygen therapy refers to getting a patient into a professional room and breathing 100% oxygen. Tetanus Toxoid Vaccine,Toxoid Vaccine,Hep B Immune Globulin,Immunoglobulin Injections FOSHAN PHARMA CO., LTD. , https://www.foshanmedicine.com
